Minerva Neurosciences | NERV - Pre Tax Profit


Minerva Neurosciences reported $22.51M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Adma Biologics USD 47.52M 7.42M Sep/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
AstraZeneca USD 3.24B 117M Sep/2025
BioCryst Pharmaceuticals USD -86.95M 73.5M Dec/2024
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Cipla INR 11.69B 6.85B Dec/2025
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD -6.94M 421K Sep/2025
CSL USD 1.4B 1.14B Jun/2025
Dynavax Technologies USD 28.42M 7.2M Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Grifols EUR 66.98M 19.92M Jun/2024
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Ionis Pharmaceuticals USD -129M 253M Sep/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Novavax USD -122.33M 286.92M Sep/2024
Pfizer USD 3.33B 290M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Takeda JPY 133.86B 105.69B Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024